Clinical Trials List
2012-09-01 - 2016-02-28
Phase III
Terminated8
ICD-10F20.9
Schizophrenia, unspecified
Long-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
Dainippon Sumitomo Pharma Co., Ltd.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chen-Chung Liu Division of Psychiatry
- CHIH-MIN LIU Division of Psychiatry
- YI-LING CHIEN Division of Psychiatry
- 謝明憲 Division of Psychiatry
- YI-TING LIN Division of Psychiatry
The Actual Total Number of Participants Enrolled
4 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Secondary efficacy measures will be assessed by the Change from baseline in the PANSS total score by subscales etc.
Inclution Criteria
- Patients who are considered by the investigator eligible for the present study with no significant safety concerns
- Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study
Exclusion Criteria
- Patients who are planning pregnancy for the expected duration of the study
The Estimated Number of Participants
-
Taiwan
340 participants
-
Global
435 participants
